Stocktoria
Sana Biotechnology, Inc. SANA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-02-04
Sana Biotechnology, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $132.0M | $215.7M | $261.8M | $285.9M | $248.6M |
| Operating income | -$250.3M | -$272.7M | -$293.1M | -$272.6M | -$356.9M |
| Income tax | $0 | — | — | — | — |
| Net income | -$244.2M | -$266.8M | -$283.3M | -$269.5M | -$355.9M |
| EPS (diluted) | $-0.96 | $-1.16 | $-1.46 | $-1.43 | $-2.14 |
| Operating cash flow | -$143.8M | -$223.2M | -$253.6M | -$290.1M | -$251.1M |
| Free cash flow | -$144.8M | -$256.6M | -$273.6M | -$310.9M | -$280.9M |
| Cash & equivalents | $71.9M | $127.6M | $133.5M | $176.8M | $253.0M |
| Total assets | $416.9M | $501.0M | $565.3M | $822.7M | $1.1B |
| Total liabilities | $256.0M | $250.5M | $277.8M | $323.4M | $400.9M |
| Shareholders' equity | $160.9M | $250.5M | $287.5M | $499.3M | $728.5M |
Source: SEC EDGAR filings · CIK 0001770121 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.